Kornimate/medical-research-clean huggingface dataset:
management of a giant lymphocele following varicose vein surgery - a case report

Conditions: Lymphocele; Varicose Veins

Summary: a 48-year-old female presented to the plastic surgery outpatient department (opd) with a history of painful, progressive swelling of the right groin and medial aspect of the right thigh for 4 months. after investigation, it was diagnosed as a giant lymphocele. a pedicled gracilis muscle flap was used to reconstruct and obliterate the cavity. there was no recurrence of the swelling. : lymphocele is a common complication after extensive vascular surgeries. in the unfortunately case of its development, prompt intervention must be done to prevent its growth and ensuing complications.


Eligibility criteria:
inclusion criteria: diagnosed case of lymphocele - exclusion criteria: none -

Keywords: lymphocele, varicose vein, gracilis muscle, sclerotherapy.
the effects of melatonin on cardiovascular and bone metabolism markers in peritoneal dialysis patients

Conditions: Peritoneal Dialysis

Summary: the aim of this double-blind randomized clinical trial is to determine the effects of melatonin on cardiovascular disease risk factors, bone metabolism markers, serum concentrations of advanced glycated end products and quality of life in peritoneal dialysis patients. forty patients from peritoneal dialysis centers will randomly assign to either melatonin or placebo group. the patients in melatonin group will receive 5 mg melatonin (as 1 tablet) daily for 10 weeks, while the placebo group will receive identical placebo. at the baseline and the end of the study,7 ml blood will be collected from each patient after a 12-14-hours fasting and serum concentrations of malondialdehyde; high sensitivity c-reactive protein; soluble intercellular adhesion molecule-1; glucose; pentosidine; carboxy-methyl lysine; procollagen 1 intact n-terminal propeptide; tartrate-resistant acid phosphatase 5b; osteoprotegerin; receptor activator of nuclear factor kappa-β ligand; intact parathyroid hormone; triglyceride; total cholesterol; high-density lipoprotein cholesterol; low-density lipoprotein cholesterol; lipoprotein-a; albumin; calcium; phosphorous; and also systolic blood pressure; diastolic blood pressure and questionnaires including quality of life; quality of sleep and depression will be assessed.


Eligibility criteria:
inclusion criteria: * continuous ambulatory peritoneal dialysis for 6 months or more * body mass index (bmi) below 35 exclusion criteria: * infectious diseases (especially peritonitis) and inflammatory diseases liver diseases * past medical history of cancer receiving glucocorticoid drugs, non-steroidal anti-inflammatory drugs * receiving melatonin supplements
knowledge, attitudes, and perceptions of a group of egyptian dental students towards artificial intelligence

Conditions: Health Knowledge, Attitudes, Practice

Summary: in the context of this ongoing ai revolution, it is essential to ensure that current and future clinical practitioners are up to date regarding this technology's current state and potential. it is valuable to assess the current attitude of clinical dentists and undergraduate students in dentistry regarding the future role of ai. to the best of the author's knowledge, there is no study about egyptian dental students' views and attitudes regarding the application of ai in dental practice. therefore, this study aimed to evaluate the attitudes and perceptions of a group of dental students in egypt towards ai.

data will be collected using a questionnaire. the survey will be distributed to dental students at the faculty of dentistry, cairo, and egyptian russian universities through google forms. the questionnaire comprised 3 sections and 22 questions. the survey consisted of a question on demographics and educational information about dental students, knowledge of and attitudes towards ai, future application areas of ai in dentistry, and topics of ai in dental education. the first part of the survey. informed consent will be obtained from all the participants before completing the questionnaire.

Eligibility criteria:
inclusion criteria: - dental students exclusion criteria: * graduates
a study to evaluate pt-523 in patients with refractory leukemia

Conditions: Leukemia

Summary: this phase i/ii, multi-centered, non-randomized, trial is designed to determine a safe dose of pt-523 for subjects, and to make preliminary evaluations on the activity of pt-523 as therapy in subjects with refractory leukemia.


Eligibility criteria:
inclusion criteria: * relapsed/refractory leukemias including acute non-lymphocytic leukemia (aml), acute lymphocytic leukemia (all), chronic lymphocytic leukemia (cll), and chronic myelogenous leukemia in blastic phase (cml-bp) for which no standard therapies are anticipated to result in a durable remission; or poor-risk myelodysplasia (mds) patients to include refractory anemia with excess blasts (raeb) or excess blasts in transformation (raebt) and chronic myelomonocytic leukemia (cmml) who are either relapsed/refractory or who refuse/are not eligible for frontline therapy. * only patients with refractory all or cml in lymphoid blastic phase are eligible for phase ii. * ecog performance status 0 - 2. * adequate organ function and bone marrow reserve. * at least 4 weeks must have elapsed from the time of major surgery. * use of appropriate contraceptive method. * signed patient informed consent. exclusion criteria: * known human immunodeficiency virus (hiv). * active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. * patients receiving any other standard or investigational treatment for their leukemia other than corticosteriods, hydroxyurea, and 6-mercaptopurine. * any medical condition which, in the opinion of the investigator, places the patient at an unacceptably high risk for toxicities.
cognitive, psychological, and physical functioning in long-covid patients with different levels of fatigue.

Conditions: Post-Acute COVID-19 Syndrome

Summary: post covid-19 usually occurs 3 months from the onset of covid-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. patients report a range of disabling symptoms such as fatigue, shortness of breath, cognitive impairment, memory loss and mental health and employment issues. this clinical heterogeneity complicates the identification of the appropriate needs and care. the aim of this cross-sectional study is to identify subgroups (clusters) of post covid patients based on clinical symptoms, demographic characteristics, levels of fatigue and physical, cognitive and psychological functioning of the individuals.


Eligibility criteria:
inclusion criteria: the participant must report current persisting symptoms (such as brain fog, anxiety, shortness of breath, headaches but also others) and indicate on the post covid-19 functional status scale that these have an impact on everyday functioning (grade 2, 3, and 4). these symptoms need to be present for more than two months. further inclusion criteria are: * fatigue severity scale (fss) score \> 4 * aged over 18 years old * willing to sign the digital informed consent * dutch speaking and dutch understanding * be tested positive for covid-19, i.e. by reverse transcription polymerase chain reaction (rt-pcr), computed tomography (ct) of the lungs, or symptom-based diagnosis by the general practitioner. exclusion criteria: * pregnant women * pacemaker, defibrillator * brain or nerve disorders * epilepsy * a copper spiral or recent bone fracture
microtransplantation for ovarian cancer

Conditions: Ovarian Cancer Recurrent

Summary: in this study, we will apply micro transplantation to the field of recurrent and advanced ovarian cancer to study the efficacy and safety.

the eligible patients are assigned to the experimental group (microtransplantation group, mst group) or the control group (ct) according to the availability of suitable donors. in mst group, peripheral blood hematopoietic stem cells from hla mismatched donors mobilized with granulocyte colony stimulating factor are infused after conventional chemotherapy and/or radiotherapy ; the ct group only received conventional chemotherapy and/or radiotherapy. according to the patient's past medical history, current tumor assessment results, and the latest cancer treatment guidelines, the individualized chemotherapy and / or radiotherapy plan for the patient is formulated after discussion by more than 3 oncologists. after each course of treatment, the efficacy and safety are evaluated. for the patients who are evaluated to be effective or stable (sd) after the first treatment, the second treatment of the same scheme will be given. those who reach the disease control level will continue to be treated for 4 courses, with an interval of 28 days. the patients who failed to achieve the improvement of sd after two cycles of chemotherapy will be withdrawn from the study. patients are allowed to receive any treatment, including symptomatic support treatment, after the end of treatment or withdrawal from the study.

Eligibility criteria:
inclusion criteria: * patients are 18-80 years old, female，regardless of race; * advanced / relapsed ovarian cancer confirmed by clinical or histopathological diagnosis; * more than two kinds of tumors are allowed; * karnofsky score ≥ 60, ecog physical status ≤ 2; * sensitive to chemotherapy or radiotherapy; * there are measurable lesions; * there are suitable hematopoietic stem cell donors exclusion criteria: * have no suitable donor or donor refused * patient refused to accept donor cells

Keywords: microtransplantation
treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells

Conditions: Systemic Lupus Erythematosus

Summary: treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells


Eligibility criteria:
inclusion criteria: * sle diagnosis (4 of 11 criteria by acr); * positive dsdna; * selena-sledai index ≥6; * active lupus nephritis; * patient can read, understand and follow the procedures. exclusion criteria: * need for dialysis; * planned renal transplantation; * any medical condition which can be associated with the high risk for the patient; * pregnancy/lactation; * chronic infections, including hepatitis b/c, tuberculosis, hiv; * any malignant tumor in the last 5 years.

Keywords: systemic lupus erythematosus mesenchymal stem cells
histopathologic effect of calcium electroporation on cancer in the skin

Conditions: Cancer

Summary: in this phase ii study we investigate the effect of calcium electroporation on cancer in the skin investigated by histopathology.

in this non randomized phase ii study, we will explore histopathological tumour cell death mechanisms in 24 patients with breast cancer metastases or other cutaneous or subcutaneous malignancy. the primary endpoint of the biopsy study is to evaluate differences in tumour infiltrating lymphocyte (til) population in tissue samples from treated cancer tumours two days after calcium electroporation treatment compared to samples taken on the day of treatment before the calcium electroporation procedure. til content in biopsies will be evaluated by pathological examination and specified in percent of cells. patients will be followed up to 3 months and depending on number of treated tumors, biopsies will be taken at different timepoints after one or two treatments with calcium electroporation. other analyses will include differences regarding tumour type, immune marker expression levels over time, vascular effects and regressive changes as well as examining changes in systemic immunological markers.

Eligibility criteria:
inclusion criteria: * trial subject must be able to understand the participant information. * histologically verified cutaneous or subcutaneous, primary or secondary cancer of any histology. * the patient can undergo any simultaneous medical treatment (endocrine therapy, chemotherapy, immunotherapy etc.). * the patient can undergo radiation therapy during the study period, provided that the treatment field does not involve the treated area. * performance status ecog/who ≤2 * at least one cutaneous or subcutaneous tumour measuring at least 5 mm. * both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch.) * signed informed consent. exclusion criteria: * pregnancy or lactation * allergy to local anaesthesia

Keywords: calcium electroporation tumor infiltrating lymphocytes cancer metastases
rg3 in combination with tace in hepatocellular carcinoma patients with high expression of notch1

Conditions: Hepatocellular Carcinoma; TACE; Notch1; Rg3

Summary: in order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of rg3 in combination with tace on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of notch1.


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed hepatocellular carcinoma. 2. high expression of notch1 in tumor tissues. exclusion criteria: no pathological evidence of hcc

Keywords: carcinoma hepatocellular notch1
evaluation of hypnosis in virtual reality on the anxiety of patients with metastatic prostate cancer over chemotherapy

Conditions: Metastatic Prostate Cancer

Summary: prostate cancer is the first cancer in men. the treatment of metastatic prostate cancer with chemotherapy is based on the intravenous administration of docetaxel chemotherapy. symptoms of anticipatory nausea, linked to anxiety caused by the treatment, may occur. hypnosis is already used to treat the anxiety of people with cancer and can help treat the symtoms of nausea and vomiting of women with breast cancer. the purpose of the study is to evaluate the effect of medical hypnosis in virtual reality on the anxiety of patients with metastatic prostate cancer receiving docetaxel chemotherapy treatment in comparison with a control group.

after verifying the patient's eligibility criteria and obtaining the signed informed consent form, the patient is randomized to the arm receiving hypnosis in virtual reality or to the control arm. the study ends after the 12 courses of docetaxel or premature termination of the study.

Eligibility criteria:
inclusion criteria: * man aged ≥ 18 years * histologically proven metastatic prostate adenocarcinoma, * patient undergoing chemotherapy according to the following conventional scheme: 12 courses of docetaxel every two weeks * patient who signed their informed consent * patient benefiting from social security coverage * patient treated and followed in the center for the duration of the study (6 months maximum). exclusion criteria: * patient participating in another clinical trial on an experimental molecule * patient who received previous chemotherapy * patient unable to submit to protocol monitoring for psychological, social, family or geographic reasons * patient deprived of their liberty or under guardianship * patient with underlying or concomitant pathology incompatible with inclusion in the trial, whether psychiatric or somatic

Keywords: virtual reality oncology chemotherapy anxiety
dextrose prolotherapy on articular cartilage

Conditions: Arthritis Knee

Summary: dextrose prolotherapy is a controversial injection therapy in sports medicine. currently, 25% hypertonic glucose solution is commonly used in clinical practice. although this method has a certain therapeutic effect, there is still some controversy about the molecular mechanism of dextrose prolotherapy. in the past, it was thought that local stimulation would increase inflammatory reactions such as local leukocyte and macrophage infiltration and restart the "self-healing mechanism." however, some studies have pointed out that this treatment can cause cell apoptosis. in my clinical work, i often perform dextrose prolotherapy. i deeply feel the importance of exploring the detailed mechanism of action of this therapy in order to apply this therapy more appropriately to patients. we believe that the concentration of 25% hypertonic glucose solution should show a stepwise decrease in the joint cavity. our preliminary cell experiment results using 2-fold serial dilutions of 25% glucose solution showed that 25%, 12% and 6% glucose solution will trigger the apoptosis of chondrocytes, vascular endothelial cells and immune cells, and will also inhibit the expression of the pro-inflammatory factor il-6. glucose solution below 3% will not have the effect of inducing apoptosis on cells. we believe that the therapeutic effect of 25% hypertonic glucose solution in the joint cavity may have cell-specific effects as the concentration changes dynamically. therefore, in this study, we will clarify the therapeutic mechanism of dextrose prolotherapy for arthritis through basic research and clinical specimen analysis. the clinical research part will use clinical synovial fluid specimens to verify the therapeutic mechanism of hypertonic glucose dissolution. the joint pain level assessment of different types of patients (oa and ra) before dextrose prolotherapy (preliminary period), 1 month after treatment (midterm period) and 3 months after treatment (late period) will be collected, and joint effusion will be measured. further analyze the cell apoptosis and concentration changes of inflammatory response factors in the liquid. we hope that through this study, we will have a clear understanding of the molecular mechanism of dextrose prolotherapy on joint component cells. this result will have reference value for the more appropriate application of dextrose prolotherapy in the treatment of human cartilage-related lesions.


Eligibility criteria:
inclusion criteria: * willing to sign a written consent form * adult men and women with arthritis exclusion criteria: * pregnant or lactating women * septic arthritis * those who have undergone joint surgery within 30 days

Keywords: dextrose prolotherapy joint pain synovial fluid
bioequivalence between we 941 od and brotizolam (lendormin®) in healthy adult males

Conditions: Healthy

Summary: the bioequivalence of we 941 od tablets prepared in oral disintegrating tablet form taken without water and brotizolam conventional tablets (lendormin® tablets) taken with water, was evaluated in healthy adult male subjects (open-labelled, 2-way cross-over study)


Eligibility criteria:
inclusion criteria: * age between 20 and 35 years * weight between 50 and 80 kg * obesity level within the range of +/- 20% of the standard weight according to the body mass index (bmi) method * judged as eligible as a study object following the screening test by the investigator * volunteers to participate in the study, who are capable of giving written informed consent exclusion criteria: * known hypersensitivity to drugs * history of drug or alcohol abuse * received other investigational drug within 4 months of the trial drug administration * had \> 400 ml of whole blood drawn within 3 months of the trial drug administration * had \> 400 ml of blood components drawn within 1 month of the trial drug administration * used any drug within 10 days of the trial drug administration * engaged in strenuous exercise within 5 days of the trial drug administration * consumed alcohol within 3 days of the trial drug administration * judged as ineligible for the study participation by the investigator for a reason other than above
left atrial posterior wall additional isolation for persistent atrial fibrillation trial

Conditions: Persistent Atrial Fibrillation; Catheter Ablation; Pulmonary Vein Isolation; Posterior Wall Isolation

Summary: the purpose for this study is to determine whether left posterior wall isolation (pwi) in addition to pulmonary vein isolation (pvi) is effective as ablation strategy for persistent atrial fibrillation (af).

pvi is cornerstone of af ablation. however, clinical outcome of only pvi in patients with persistent af is insufficient due to af substrate extending to left atrium. strategy of catheter ablation for persistent af is not established despite attempts of numerous left atrial substrate modifications. additional pwi on pvi is one of expected effective strategies for persistent af, because pw originated from common tissue of pv and is considered to play a part in af trigger and maintenance. however, this strategy is also not established in the recent international consensus statement. following two reasons are considered. one is the procedural difficulty in creating durable pwi, and another is the existence of patients who can recover by only pvi. the latest technology, ablation index, can create durable pvi, and may create durable pwi. several reports suggested that pvi only strategy was sufficient in the patients with persistent af who could maintain sinus rhythm after pharmacological or electrical cardioversion. therefore, we planed this randomized clinical trial that compared between pvi alone and additional pwi on pvi using ablation index in the patients with persistent af without pharmacological sinus rhythm conversion.

Eligibility criteria:
inclusion criteria: * patients scheduled for first catheter ablation of persistent atrial fibrillation * patients without conversion to sinus rhythm within 30 days after antiarrhythmic drug administration * patients with persisting duration of atrial fibrillation less than 3 years * patients with left atrial diameter less than 50mm * patients who can be followed up for 18 months * patients with written informed consent exclusion criteria: * patients who can not be received adequate anticoagulation therapy * patients with history of myocardial infarction within 6 months * patients with history of open heart surgery * patients scheduled for open heart surgery * patients with severe valvular heart disease * patients during pregnancy * patients with expected life expectancy less than 1 year due to malignancy or non-cardiovascular disease * patients considered unsuitable for study by the attending physician

Keywords: persistent atrial fibrillation catheter ablation pulmonary vein isolation posterior wall isolation
foam-study, cost minimization study comparing surgery versus duplex guided foam sclerotherapy of varicose veins

Conditions: Varicose Vein Disease

Summary: varicose vein disease is a common health problem, which causes much discomfort to patients. nowadays treatment modalities for greater saphenous veins include surgery and duplex guided foam sclerotherapy. these are two equally accepted and applied treatments for the same patient population. choice of treatment often depends on the referral preference of the general practitioner. until now data are missing which treatment is more cost effective. the current proposal aims at comparing the effects, costs and patient preferences between duplex guided foam sclerotherapy and surgery in the treatment of greater varicose veins.


Eligibility criteria:
inclusion criteria: * incompetence of great saphenous vein for minimal 20 cm * life expectancy at least 3 years * open and competent deep venous system * willing to undergo both treatments exclusion criteria: * active ulcer * signs of deep venous thrombosis with duplex * incompetence of the deep venous system

Keywords: incompetence of the great saphenous vein.